Thymosin alpha-1 is a peptide 28 amino acids long, first pulled out of calf thymus extract in the 1970s. It acts on how T cells mature and signal.
What matters first
Why people look it up
It is sold for immune support: long COVID, chronic infection, and general resilience.
What the evidence shows
It carries a large trial record, and that record is about acutely unwell hospital patients rather than healthy adults. Under the name thymalfasin it is an approved medicine in several countries, mainly for chronic hepatitis B. Its largest trial gave it to 1,106 people with sepsis. By day 28, 23.4% had died on the drug against 24.1% on placebo.
Dose status
Thymosin alpha-1 is not FDA-approved, so no dosing label exists for it. The sections below explain what researchers tested and what remains unknown.
Thymosin alpha-1 at a glance: foreign approval or limited human data, dosing basis, regulatory status, safety coverage, and cited-source count. These details summarize the available sources; they are not treatment recommendations.
Evidence snapshot
Foreign approval or limited human data
The fastest way to see what kind of evidence this page is built on.
Regulation
Not FDA-approvedNo US prescribing label
Dose source
Human study4 reported dose rows
Safety evidence
3 listed safety findingsCommon and serious effects shown apart
Thymosin alpha-1 at a glance: foreign approval or limited human data, dosing basis, regulatory status, safety coverage, and cited-source count. These details summarize the available sources; they are not treatment recommendations.
Medically reviewed by Jennifer Montecillo, MD · non-practicing medical reviewer·Reviewed 2026-08-12·open the primary sources
What is known about Thymosin alpha-1
Thymosin alpha-1 is a peptide that affects how T cells mature and send signals. It is sold as thymalfasin in several countries, mainly for chronic hepatitis B. It has never been approved in the United States. Large trials used 1.6 mg under the skin. The timing changed by condition.
Thymosin alpha-1 research and regulatory details: evidence quality, approval status, doses, handling, and presentation.
Topic
Value
Strongest source
limited human data
FDA approval
Not FDA-approved
Studied dosing
1.6 mg twice a week, for 26 or 52 weeks, in a 98-patient randomized trial in chronic hepatitis B— from clinical trials
Studied dosing
1.6 mg once daily for the first week, then twice a week to week 12, in a 120-patient randomized trial in hepatitis-B-related acute-on-chronic liver failure— from clinical trials
Studied dosing
1.6 mg every 12 hours for up to seven days — the regimen of the 1,106-participant phase 3 trial that found no mortality benefit— from clinical trials
Studied dosing
1.6–6.4 mg on days 8–11 and 15–18 of each 28-day cycle — the three arms (1.6, 3.2 and 6.4 mg) of a 488-participant phase 2 dose-ranging trial in metastatic melanoma— from clinical trials
Typical vials
5 mg · 10 mg
Every row links back to a source listed below. These facts are for reference, not a personal recommendation.
What the evidence for Thymosin alpha-1 is
People have received this compound in a documented setting, or it has approval outside the United States. The available human evidence is still too limited to show a clear dose-and-result pattern for US use.
limited human data
What it establishes
It shows that people have received it and that some human information exists.
What it does not establish
It does not prove that the same dose is appropriate in the United States or that uncommon and long-term risks are known.
Check the country, study size and reason it was used. Do not treat limited human data as an FDA-approved schedule.
Where Thymosin alpha-1 is in clinical trials
51 registered studies; the program has reached phase 4, and 9 are still enrolling.
The soonest a running study expects to finish measuring people is December 2026. That is when the sponsor expects to finish collecting the main measurement. It is not a results date, and not a date anything goes on sale.
Phase 4Completed
Thymosin Alpha 1 in the Prevention of Pancreatic Infection Following Acute Necrotizing Pancreatitis
Weiqin Li · Pancreatitis, Acute Necrotizing · 508 participants · started March 2018
Searched under the name thymosin alpha 1, which is how the registry files it.
A registered study means a sponsor filed a plan and started enrolling. It is not evidence the drug works, and most drugs tested in people never reach a pharmacy. Sponsors write and update these sources themselves; the National Library of Medicine publishes them without checking them.
An approval elsewhere is real evidence, and it is not an American one.
The review standard, the permitted claims and the safety follow-up all belong to the jurisdiction that granted it. The practical gap shows up in the vial. Trials dissolve 1.6 mg of powder in 1 mL and inject that.
Research vials sold under this name hold 5 mg or 10 mg. So one 10 mg vial holds more than six trial doses. Any quantity quoted from the approved labeling describes a different container entirely.
Approved outside the United States only — no American labeling exists for any use
The largest trial included 1,106 people with sepsis. It found no survival benefit
These studies treated very ill hospital patients. None tested healthy adults, longevity or general immune support
Trials mixed 1.6 mg in 1 mL. Research vials hold 5 mg or 10 mg, so the amounts do not transfer
Acts on T-cell function, so it is not a neutral addition for anyone with autoimmune disease or on immunosuppressive treatment
Research-grade material is not the pharmaceutical product any approval or trial refers to
Questions about Thymosin alpha-1
Is Thymosin alpha-1 FDA-approved?
No. There is no prescribing label for it, so no approved dose exists — the regulatory status section above has the detail.
How is Thymosin alpha-1 taken?
By injection under the skin, twice a week.
How does Thymosin alpha-1 differ from the other compounds in this class?
Thymosin alpha-1 has been studied in people, but it works through a different system from GLP-1 and amylin drugs. Its doses and results are not directly comparable with theirs.
What is not known about Thymosin alpha-1?
It does not prove that the same dose is appropriate in the United States or that uncommon and long-term risks are known.
Questions readers ask
What is the peptide thymosin alpha-1 used for?
Outside the United States it is an approved medicine called thymalfasin, used mainly in chronic hepatitis B and as an immune adjuvant. Registered trials have also run it in hepatitis C, liver failure, sepsis, pancreatitis and cancer care.
It acts on how T cells mature and signal. Every regimen on record went to acutely unwell people in hospital — none studied healthy adults, longevity or general immune support.
How long does it take thymosin alpha 1 to work?
Trials report course length, not a time to onset. Sepsis used one dose every 12 hours, for up to seven days. Chronic hepatitis B used twice a week, for 26 or 52 weeks.
The liver-failure trial gave it daily for a week, then twice a week to week 12. So the schedule moves with the illness and the quantity holds still, at 1.6 mg.
What are the risks of using thymosin alpha 1?
In the largest trial, unwanted events were just as common on placebo: 66.4% against 67.6%, among 1,089 adults with sepsis. Serious ones ran 26.8% against 29.3%, with no meaningful difference.
The sharper risks sit off that table. It acts on T-cell function, so it is not a neutral addition for anyone with autoimmune disease or on immune-suppressing treatment.
What is the best peptide for boosting the immune system?
No trial has ranked peptides against each other for immune function, so nobody can name a best one honestly.
Thymosin alpha-1 has the largest registered record of the immune-facing peptides here, and it is approved abroad as thymalfasin. Its biggest test still failed: a 1,106-participant phase 3 in sepsis found no survival benefit.
6primary sources, each with the day we read it — open the documents used on this page
